A shortage can begin before a storm, then become much harder to manage when a concentrated production location is disrupted. The unexpected part is not only the weather event. It is the way an existing fragility and a geographic concentration meet.
Fact
Source record. FDA described a sterile-saline shortage that was worsened by the Puerto Rico disruption. It did not object to temporary importation by manufacturers from multiple countries and expedited related reviews; FDA itself did not import the supplies. It also reported the approximate share of medicines consumed by Americans, by dollar value, manufactured in Puerto Rico.
The source does not say that every product made in Puerto Rico was unavailable or that every provider experienced the same shortage. Its bounded value is the connection between an existing supply condition, a concentrated manufacturing location, and an emergency response that crossed national supply routes.
Signal
The concentration question has two parts: where a product is made and what condition already exists in the wider supply system. A disruption that would be manageable with slack can become acute where alternatives, inventories, or approvals are already constrained.
What happened
The FDA record describes a hurricane-season disruption that worsened a sterile-saline shortage. In response, FDA did not object to temporary importation by manufacturers from multiple countries and expedited related reviews. The reported Puerto Rico manufacturing share puts the event in a wider medicines-supply context.
PARAVEILUX inference. The dependency chain is regional disruption → concentrated supply base meets an existing shortage → emergency import response → a public-facing availability problem. The useful question for an owner is not whether an event is dramatic enough to matter. It is which product, location, and pre-existing constraint would make the organisation dependent on a public or regulatory response.
The hidden variable
The hidden variable is one island’s manufacturing share plus an existing shortage. Supplier diversification can appear adequate when measured by supplier names but not by manufacturing location, product category, inventory, qualification, and the time needed to bring an alternative supply path into use.
What this source does not prove
FDA’s material reports national supply effects. It does not prove an individual provider’s product availability, commercial loss, insurance treatment, contractual right, or recovery date. It also does not establish current product availability.
Owner Q&A
Which products need a concentration map?
Start with products whose absence changes service delivery, safety, production, or customer commitments. For each, map supplier, manufacturing location, approved alternatives, inventory, transport, and the time needed to qualify a replacement.
Can an emergency temporary-import response be treated as a normal contingency plan?
No. It may be relevant context, but it depends on the product, regulatory pathway, market, and facts then present. It is not a substitute for current supply and qualification evidence.
Action boundary
Use this as a neutral review prompt: “Which geographically concentrated supplier can create a public-facing shortage?” The cited source does not prescribe an answer for another organization; current facts and appropriate specialist advice govern any action.
Next verification
Reconfirm the current source, inventory, manufacturing, and alternative-supply information before treating a historical emergency response as a present operating option.
Limitations
The factual record is drawn from FDA shortage material and 2017 congressional testimony. It reports FDA’s historical no-objection and expedited-review actions and national conditions, not individual firm losses or current supply status.
This is general risk education, not legal, insurance, financial, technical, or professional advice. Verify the current sources, product status, contracts, and applicable requirements for the actual decision.